Gastrin secretion in normal subjects and diabetes patients is inhibited by glucagon-like peptide 1: a role in the gastric side effects of GLP-1-derived drugs?-Reference-Cited by-同舟云学术

Gastrin secretion in normal subjects and diabetes patients is inhibited by glucagon-like peptide 1: a role in the gastric side effects of GLP-1-derived drugs?

Published:2019-11-14 Issue:12 Volume:54 Page:1448-1451
ISSN:0036-5521
Container-title:Scandinavian Journal of Gastroenterology
language:en
Short-container-title:Scandinavian Journal of Gastroenterology

Author:

Rehfeld Jens F.¹,Knop Filip K.²,Asmar Meena³

Affiliation:

1. Department of Clinical Biochemistry, University of Copenhagen, Rigshospitalet, Denmark;

2. Center for Clinical Metabolic Research, Gentofte Hospital; Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen; and Steno Diabetes Center Copenhagen, Hellerup, Denmark;

3. Department of Clinical Physiology, Bispebjerg Hospital, Steno Diabetes Center, Odense University Hospital, Denmark, Copenhagen, Denmark

Publisher

Informa UK Limited

Subject

Gastroenterology

Link

https://www.tandfonline.com/doi/pdf/10.1080/00365521.2019.1690673

Reference37 articles.

1. Gastrointestinal hormone research – with a Scandinavian annotation

2. Gastrointestinal Hormones and Their Targets

3. Somatostatin Cell Processes as Pathways for Paracrine Secretion

4. Altered control of gastric acid secretion in gastrin-cholecystokinin double mutant mice

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database;Frontiers in Endocrinology;2022-12-07

2. Is a Non-Caloric Sweetener-Free Diet Good to Treat Functional Gastrointestinal Disorder Symptoms? A Randomized Controlled Trial;Nutrients;2022-03-05

3. Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study;Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy;2022-01

4. Effects of L‐arabinose by hypoglycemic and modulating gut microbiome in a high‐fat diet‐ and streptozotocin‐induced mouse model of type 2 diabetes mellitus;Journal of Food Biochemistry;2021-11-14

5. Exenatide Microspheres for Monthly Controlled-Release Aided by Magnesium Hydroxide;Pharmaceutics;2021-05-30